Published in Cancer Weekly, October 3rd, 2006
Under terms of the agreement, Kingsbridge has committed to provide up to $25 million of capital during the next 3 years through the purchase of newly issued shares of Micromet's common stock. Micromet will determine the timing and amount of any CEFF financings, subject to certain conditions.
Micromet's most advanced product candidate is...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.